Litcius/Paper detail

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Sanjay Ramakrishnan, Dan V. Nicolau, Beverly Langford, Mahdi Mahdi, Helen Jeffers, Christine Mwasuku, Karolina Krassowska, Robin Fox, Ian Binnian, Victoria Glover, Stephen Bright, Christopher Butler, Jennifer Cane, Andreas Halner, Philippa C. Matthews, Louise Donnelly, Jodie L. Simpson, Jonathan Baker, Nabil T. Fadai, Stefan Peterson, Thomas Bengtsson, Peter J. Barnes, Richard Russell, Mona Bafadhel

2021The Lancet Respiratory Medicine434 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOpen labelBudesonideCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Randomized controlled trialMEDLINEIntensive care medicineInternal medicineVirologyAsthmaInfectious disease (medical specialty)DiseasePolitical scienceOutbreakLawCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Respiratory viral infections research
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial | Litcius